Portfolio Companies

  • AI/ML Ops
    Architecture, Engineering, and Construction
    B2B GTM
    B2C MarTech & Customer Support
    BioTech/Therapeutics
    Consumer
    Cybersecurity
    Data & Data Mgmt.
    DevOps
    eCommerce Enablement
    Education
    Energy & Climate
    Finance & Accounting
    Financial Services
    Gaming
    Government
    Healthcare
    Human Capital
    IT Mgmt
    Legal & Compliance
    Manufacturing
    Marketplace
    Other Vertical Market SaaS
    Payments
    Product & Process Management
    Real Estate
    Supply Chain & Logistics
    Web3
  • North America
    Africa
    Western Europe
    Eastern Europe
    Asia Pacific
    Israel
    South America
  • Current Investment
    Prior Investment

Limerick, No Data Available, Ireland

Amsterdam, No Data Available, Netherlands

Tel Aviv, No Data Available, Israel

Bonn, No Data Available, Germany

Miami, Florida, U.S.

San Francisco, California, U.S.

Insight Partners is an awesome firm that shares many of our values, and we’ve been grateful to have them as partners on this journey of building a great company based on a great product.
Eran Zinman
Co-Founder & CEO Monday.com*

London, No Data Available, U.K.

Lehi, Utah, U.S.

Farmington, Utah, U.S.

Espressive logo

San Francisco, California, U.S.

Wilmington, North Carolina, U.S.

San Francisco, California, U.S.

Iterative Scopes is pioneering the application of precision medicine to gastroenterology with the aim of enhancing colorectal cancer screenings. The technology is also designed to help optimize clinical trials investigating treatment of inflammatory bowel disease. Its powerful, proprietary artificial intelligence and computer vision technologies have the potential to improve the accuracy and consistency of endoscopy readings. Iterative Scopes is initially applying these advances to improve polyp detection for colorectal cancer screenings and standardizing disease severity characterization for inflammatory bowel disease (IBD). Longer term, the company plans to establish more meaningful endpoints for GI diseases, which can be better predictors of therapeutic response and disease outcomes. Spun out of MIT in 2017, the company is based in Cambridge, Massachusetts.

Investment Team Lonne Jaffe Teddie Wardi
Sectors Healthcare Payor / Provider
Tags Applied AI
Status Current Investment